J3245 Injection., tildrakizumab, 1 milligrams
J-Codes
Also known as: tildrakizumab, Ilumya, interleukin-23 inhibitor
Tildrakizumab 1 milligram injection is a monoclonal antibody targeting interleukin-23 used for moderate to severe plaque psoriasis and psoriatic arthritis treatment.
Clinical Context
Indicated for moderate to severe plaque psoriasis and psoriatic arthritis. Biologic therapy targeting interleukin-23 pathway. Administered subcutaneously every 12 weeks after initial loading doses.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.